Aurobindo Pharma Ltd 2021 AR2
The report highlights Aurobindo Pharma Limited's financial and ESG performance for the fiscal year 2020-21. Financially, the company achieved record revenues of ₹247,746 million, representing a 7% year-on-year growth, and transitioned into a net cash surplus position. On the environmental front, the company reduced its energy consumption by 5.16% (338,332 GJ) and carbon emissions by 5.5% (52,725 tCO2e) compared to the previous year. Socially, women represented 9% of the workforce, and the company invested ₹588 million in CSR initiatives, impacting over 0.92 million lives. Additionally, the Board maintained 45% independent directors, including two women.
Company: Aurobindo Pharma Ltd
Sector: Manufacturing
Country: India
Year: 2021
Type: AR2
Pages: 300
Back to company
Aurobindo Pharma Ltd
Annual Report
The report highlights Aurobindo Pharma Limited's financial and ESG performance for the fiscal year 2020-21. Financially, the company achieved record revenues of ₹247,746 million, representing a 7% year-on-year growth, and transitioned into a net cash surplus position. On the environmental front, the company reduced its energy consumption by 5.16% (338,332 GJ) and carbon emissions by 5.5% (52,725 tCO2e) compared to the previous year. Socially, women represented 9% of the workforce, and the company invested ₹588 million in CSR initiatives, impacting over 0.92 million lives. Additionally, the Board maintained 45% independent directors, including two women.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees